BACKGROUND: By pre-synaptic stimulation of DA(2)-dopaminergic and alpha(2)-adrenergic receptors, nolomirole inhibits norepinephrine secretion from sympathetic nerve endings. We performed a clinical study with nolomirole in patients with heart failure (HF). METHODS: The study was designed as a multicentre, double blind, parallel group trial of 5 mg b.i.d. of nolomirole (n=501) versus placebo (n=499) in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. The primary endpoint was time to all cause death or hospitalisation for HF, whichever came first. The study was event driven and required 420 primary events. The study was completed as scheduled. RESULTS:Mean age of patients was 70 years, and 73% were male. Heart rate and blood pressure were not different in the two treatment groups. There were no changes in blood pressure. There were 233 primary events in the nolomirole group versus 208 in the placebo group (p=0.1). There were 142/145 deaths and 369/374 all cause hospitalisations in the nolomirole/placebo groups. There were no differences in walking distance, quality of life or NYHA class. CONCLUSION: A dose of 5 mg b.i.d. of nolomirole was not beneficial (or harmful) in patients with heart failure.
RCT Entities:
BACKGROUND: By pre-synaptic stimulation of DA(2)-dopaminergic and alpha(2)-adrenergic receptors, nolomirole inhibits norepinephrine secretion from sympathetic nerve endings. We performed a clinical study with nolomirole in patients with heart failure (HF). METHODS: The study was designed as a multicentre, double blind, parallel group trial of 5 mg b.i.d. of nolomirole (n=501) versus placebo (n=499) in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. The primary endpoint was time to all cause death or hospitalisation for HF, whichever came first. The study was event driven and required 420 primary events. The study was completed as scheduled. RESULTS: Mean age of patients was 70 years, and 73% were male. Heart rate and blood pressure were not different in the two treatment groups. There were no changes in blood pressure. There were 233 primary events in the nolomirole group versus 208 in the placebo group (p=0.1). There were 142/145 deaths and 369/374 all cause hospitalisations in the nolomirole/placebo groups. There were no differences in walking distance, quality of life or NYHA class. CONCLUSION: A dose of 5 mg b.i.d. of nolomirole was not beneficial (or harmful) in patients with heart failure.
Authors: Morten Petersen; Jon T Andersen; Brian R Hjelvang; Kasper Broedbaek; Shoaib Afzal; Mette Nyegaard; Anders D Børglum; Steen Stender; Lars Køber; Christian Torp-Pedersen; Henrik E Poulsen Journal: Br J Clin Pharmacol Date: 2011-04 Impact factor: 4.335
Authors: Daniel V Møller; Redi Pecini; Finn Gustafsson; Christian Hassager; Paula Hedley; Cathrine Jespersgaard; Christian Torp-Pedersen; Michael Christiansen; Lars V Køber Journal: BMC Med Genet Date: 2010-07-29 Impact factor: 2.103
Authors: Charlotte Andersson; Gunnar H Gislason; Peter Weeke; Jesper Kjaergaard; Christian Hassager; Dilek Akkan; Jacob E Møller; Lars Køber; Christian Torp-Pedersen Journal: BMC Cardiovasc Disord Date: 2012-04-25 Impact factor: 2.298
Authors: Jesper Kjaergaard; Kasper K Iversen; Dilek Akkan; Jacob Eifer Møller; Lars V Køber; Christian Torp-Pedersen; Christian Hassager Journal: Cardiovasc Ultrasound Date: 2009-11-04 Impact factor: 2.062
Authors: Morten Schou; Jesper Kjaergaard; Christian Torp-Pedersen; Christian Hassager; Finn Gustafsson; Dilek Akkan; Jacob E Moller; Lars Kober Journal: BMC Nephrol Date: 2013-12-03 Impact factor: 2.388
Authors: Karl Emil Nelveg-Kristensen; Majbritt Busk Madsen; Christian Torp-Pedersen; Lars Køber; Martin Egfjord; Henrik Berg Rasmussen; Peter Riis Hansen Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240